TriangleNCT01774721 · CITED IN SOURCE DOCUMENTS
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2023-11-14
This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor EGFR-activating mutation (s). Analyses of primary objective (Progression Free Survival) will be done as defined in the protocol.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review
Overall Survival (OS)
OS at 30 Months (OS30m)
Progression Free Survival (PFS) Based on Investigator Assessment
Number of Participants With Best Overall Response (BOR) Based on IRC Review
Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment
Duration of Response (DoR)
Objective Response Rate (ORR) Based on IRC Review
Objective Response Rate (ORR) Based on Investigator Assessment
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology
Number of Participants With Laboratory Test Abnormalities: Urinalysis
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)
Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)
Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough
Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)
Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265
Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265
Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265
Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265
Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265
Apparent Clearance (CL) of Dacomitinib
Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Evidence of histo or cytopathology confirmed, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21). * It is acceptable for subjects with the presence of the exon 20 T790M mutation together with either EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21) to be included in this study * No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Minimum of 12 months disease free interval between completion of neoadjuvant/adjuvant systemic therapy and recurrence of NSCLC * Adequate tissue sample must be available for central analyses. * Adequate renal, hematologic, liver function. * ECOG PS of 0-1. * Radiologically measurable disease. Exclusion Criteria: * Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer. * Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation. * Any history of brain metastases or leptomeningeal metastases. * Any previous anti-cancer systemic treatment of early, locally advanced, or metastatic NSCLC. * Any surgery(not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments * Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug. * Current enrollment in another therapeutic clinical study. * History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease * Uncontrolled medical disorders. * Prior malignancy and concurrent malignancy except for non melanoma skin cancer or in-situ cervical cancer with no evidence of active disease. * Use of narrow therapeutic index drugs that are CYP2D6 substrates from screening to randomization.
- healthy Volunteers
- false
- maximum Age
- 99 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
- intervention Names
- Drug: Dacomitinib (PF-00299804)
- label
- Dacomitinib (PF-00299804)
- type
- EXPERIMENTAL
- description
- Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
- intervention Names
- Drug: Gefitinib
- label
- gefitinib
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Dacomitinib (PF-00299804)
- description
- Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
- name
- Dacomitinib (PF-00299804)
- other Names
- Dacomitinib
- type
- DRUG
- arm Group Labels
- gefitinib
- description
- Gefitinib 250 mg tablets, continuous oral daily dosing.
- name
- Gefitinib
- other Names
- Iressa
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 452
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- PFS: time from randomization to date of progression of disease (PD) as determined by IRC review as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD: \>=20% increase in sum of diameters of target lesions (TLs), referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions; unequivocal progression of existing non TLs. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.
- measure
- Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)
- secondary Outcomes
- description
- OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS (month)=\[death date or last known alive date - randomization date + 1\]/30.4375.
- measure
- Overall Survival (OS)
- time Frame
- From randomization until death or last date known as alive, up to 45 months
- description
- OS30m was defined as the probability of a participant being alive at 30 months from date of randomization.
- measure
- OS at 30 Months (OS30m)
- time Frame
- Up to 30 months from date of randomization
- description
- PFS: time from randomization to date of PD as determined by investigator assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD for target lesions: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm; for non-target lesions: unequivocal progression of pre-existing lesions. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.
- measure
- Progression Free Survival (PFS) Based on Investigator Assessment
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)
- description
- BOR for CR/PR:\>=1 objective status (OBS) of CR/PR documented before PD; SD:\>=1 OBS of stable documented \>=8 weeks (wks) post treatment \& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\<10 mm short axis); PR:\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions;unequivocal progression of existing non TLs.
- measure
- Number of Participants With Best Overall Response (BOR) Based on IRC Review
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)
- description
- BOR for CR/PR:\>=1 objective status (OBS) of CR/PR documented before PD; SD:\>=1 OBS of stable documented \>=8 weeks (wks) post treatment \& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\<10 mm short axis); PR:\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions;unequivocal progression of existing non TLs.
- measure
- Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)
- description
- DoR was defined as time from first documentation of objective response(CR or PR, whichever occurred first)to date of PD/death from any cause, whichever occurred first. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\<10 mm short axis); PR:\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions; unequivocal progression of existing non TLs. DoR was recorded based on IRC review and investigator's assessment and summarized for subgroup of participants with objective disease response.
- measure
- Duration of Response (DoR)
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)
- description
- Percentage of participants with a BOR of either CR or PR based on IRC review recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\<10 mm short axis); PR:\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions; unequivocal progression of existing non TLs.
- measure
- Objective Response Rate (ORR) Based on IRC Review
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)
- description
- Percentage of participants with a BOR of either CR or PR based on investigator assessment recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\<10 mm short axis); PR:\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \>=5 mm, appearance of \>=1 new lesions; unequivocal progression of existing non TLs.
- measure
- Objective Response Rate (ORR) Based on Investigator Assessment
- time Frame
- Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)
- description
- An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non- serious adverse events. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
- measure
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
- time Frame
- From randomization until death or last date known as alive, up to 91 months
- description
- Parameters included anaemia, activated partial thromboplastin time, haemoglobin, international normalized ratio, lymphocyte count, lymphopenia, neutrophils (absolute), platelets, prothrombin time and white blood cells. Biochemistry parameters included alanine aminotransferase (increased), alkaline phosphatase (increased), aspartate aminotransferase (increased), bilirubin (total), creatinine (increased), hypercalcaemia, hyperglycaemia, hyperkalaemia, hypermagnesaemia, hypernatraemia, hypoalbuminaemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesaemia, hyponatraemia. Test abnormalities were graded by AEs according to the Common Terminology Criteria for Adverse Events(NCI CTCAE) version 4.03 as Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening; Grade 5=death related to AE. Only categories with at least 1 participant with abnormality are reported in this outcome measure.
- measure
- Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology
- time Frame
- From randomization until death or last date known as alive, up to 61 months
- description
- Urinalysis parameter included urine protein, urine blood/haemoglobin, urine glucose and urine sediment. Test abnormalities was defined as deviation from normal range (higher or lower). Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimole per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/haemoglobin abnormality was defined as presence and absence of blood/haemoglobin in urine of participants. Urine sediment abnormality was defined as the presence of any bacteria, casts, crystals, and epithelial cells. Only categories with at least 1 participant with abnormality are reported in this outcome measure.
- measure
- Number of Participants With Laboratory Test Abnormalities: Urinalysis
- time Frame
- From randomization until death or last date known as alive, up to 61 months
- description
- Criteria for vital signs abnormalities: postbaseline pulse rate less than (\<) 50 beats per minute (bpm) or greater than (\>)130 bpm and maximum increase from baseline in pulse rate \>=30 bpm and maximum decrease from baseline in pulse rate \<=30 bpm. Systolic blood pressure (BP) of maximum increase from baseline (MIB) \>=40 millimeters of mercury (mmHg), maximum decrease from baseline (MDB) in systolic blood pressure =\<60 mmHg. Diastolic blood pressure of MIB \>=20 mmHg and MDB in diastolic blood pressure \>-40 and =\<-20 mm Hg. And MDB in diastolic BP\<=-40 mmHg. Only categories with at least 1 participant with abnormality are reported in this outcome measure.
- measure
- Number of Participants With Clinically Significant Abnormalities in Vital Signs
- time Frame
- From randomization until death or last date known as alive, up to 61 months
Full study description
- brief Summary
- This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor EGFR-activating mutation (s). Analyses of primary objective (Progression Free Survival) will be done as defined in the protocol.
- detailed Description
- 452 patients were randomized in a 1:1 ratio between dacomitinib (PF-00299804 ) vs. gefitinib.
Source references
- references
- citation
- Pu X, Li J, Zhang B, Zhang J, K Mok TS, Nakagawa K, Rosell R, Cheng Y, Zhou X, Miglorino MR, Niho S, Lee KH, Corral J, Pluzanski A, Li J, Linke R, Pan F, Tang Y, Tan W, Wu L. Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncol. 2024;20(37):2971-2982. doi: 10.1080/14796694.2024.2404762. Epub 2024 Oct 3.
- pmid
- 39360943
- type
- DERIVED
- citation
- Li J, Nickens D, Wilner K, Tan W. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. Oncol Ther. 2021 Dec;9(2):525-539. doi: 10.1007/s40487-021-00156-2. Epub 2021 Jun 13.
- pmid
- 34120312
- type
- DERIVED
- citation
- Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, Wong CH, Tang Y, Zhu F, Wilner KD, Wu YL. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 2021 Apr;154:176-185. doi: 10.1016/j.lungcan.2021.02.025. Epub 2021 Feb 23.
- pmid
- 33721611
- type
- DERIVED
- citation
- Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. doi: 10.1007/s40265-020-01441-6.
- pmid
- 33331989
- type
- DERIVED
- citation
- Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2019 Aug;15(24):2795-2805. doi: 10.2217/fon-2019-0299. Epub 2019 Jul 17.
- pmid
- 31313942
- type
- DERIVED
- citation
- Nagano T, Tachihara M, Nishimura Y. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Drugs Today (Barc). 2019 Apr;55(4):231-236. doi: 10.1358/dot.2019.55.4.2965337.
- pmid
- 31050691
- type
- DERIVED
- citation
- Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.
- pmid
- 29864379
- type
- DERIVED
- citation
- Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.
- pmid
- 28958502
- type
- DERIVED
- citation
- Ramalingam SS, O'Byrne K, Boyer M, Mok T, Janne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9. doi: 10.1093/annonc/mdv593. Epub 2016 Jan 13.
- pmid
- 26768165
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-097c8f3381962389a3ea
- requested nct id
- NCT01774721
- primary nct id
- NCT01774721
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- payload sha256
- d2061ff66f4fa6d9f21d90a54823d55da51648f7688246731d22d8f593396394
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-097c8f3381962389a3ea
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01774721
- occurrences
- context exact
- ">Evidence (dacomitinib): </p> <div class="pdq-content-list"><ol id="_485668"><li>A multicenter open-label, phase III trial (<a href="/clinicaltrials/NCT01774721">ARCHER 1050</a> [NCT01774721]) compared dacomitinib, a second-generation, irreversible EGFR TKI, administered orally at a dose of 45 mg per day with gefitinib
- end
- 490265
- exact text
- NCT01774721
- start
- 490254
- context exact
- <div class="pdq-content-list"><ol id="_485668"><li>A multicenter open-label, phase III trial (<a href="/clinicaltrials/NCT01774721">ARCHER 1050</a> [NCT01774721]) compared dacomitinib, a second-generation, irreversible EGFR TKI, administered orally at a dose of 45 mg per day with gefitinib administered orally at a dose
- end
- 490295
- exact text
- NCT01774721
- start
- 490284
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/11a3437f29dc92742e.html
- source file sha256
- 6c0293d896ac3f4fa1f72bc232cb43756a1127a408b137ddfab0e3cfa54a997a
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:59.782436+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 96af5062fe49c6481bdc1ef6946e69939f30c810b02e368845c837ccf6c0977c
- source title
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 15, 2025
- datetime
- 2025-05-15T12:00:00Z
- display
- May 15, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-6aaa9f283561698bf175
- requested nct id
- NCT01774721
- primary nct id
- NCT01774721
- source kind
- fda_spl_label
- source record id
- 3ffd0da1-5601-4ecc-a8fb-f484693cb4c5
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- 481f1e13dd833adef4329df6e71132fe4b5d07c76c67f938f3b1aae0cba46da2
- payload
- application numbers
- NDA211288
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-6aaa9f283561698bf175
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01774721
- occurrences
- context exact
- 14 CLINICAL STUDIES The efficacy of VIZIMPRO was demonstrated in a randomized, multicenter, multinational, open-label study (ARCHER 1050; [NCT01774721]). Patients were required to have unresectable, metastatic NSCLC with no prior therapy for metastatic disease or recurrent disease with a minimum of 12 months
- end
- 150
- exact text
- NCT01774721
- start
- 139
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/40/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 3ffd0da1-5601-4ecc-a8fb-f484693cb4c5
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 246667bf9b3d7ca4691b284cd393121c8c33bb62e37df4f823615ef81bfed9b9
- spl effective time
- 20260623
- spl set id
- 4ab27d2f-e385-4e9c-b324-fa69c10b855a
Preserved source evidence · Not medical advice